Cytotheryx vs Genentech

Side-by-side comparison of AI visibility scores, market position, and capabilities

Genentech leads in AI visibility (85 vs 23)
Cytotheryx logo

Cytotheryx

EmergingBioTech

Cell Therapy / Liver Disease

Raised $60M Series A (Jan 2026) led by Ouroboros Capital. Mayo Clinic spinout. Engineered pigs as bio-incubators for human hepatocyte production at scale.

AI VisibilityBeta
Overall Score
D23
Category Rank
#1 of 1
AI Consensus
71%
Trend
up
Per Platform
ChatGPT
26
Perplexity
15
Gemini
21

About

Cytotheryx is a Mayo Clinic spinout developing human hepatocytes (liver cells) produced at scale using genetically engineered pigs as bio-incubators. The company raised $60 million in Series A financing in January 2026 led by Ouroboros Capital, with GMP (Good Manufacturing Practice) manufacturing expansion underway to support both its acute liver failure support program and transplant-grade cell therapy pipeline.

Full profile
Genentech logo

Genentech

LeaderLife Sciences & BioTech

Biopharmaceuticals

Roche subsidiary and founding biotech; invented the biologics industry with recombinant DNA. Blockbuster oncology franchise includes Herceptin, Avastin, Rituxan, and Tecentriq.

AI VisibilityBeta
Overall Score
A85
Category Rank
#1 of 2
AI Consensus
57%
Trend
up
Per Platform
ChatGPT
77
Perplexity
95
Gemini
83

About

Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching the modern biotechnology industry. Acquired by Roche in 2009 for $46.8 billion, Genentech continues to operate with significant R&D autonomy as the US hub for Roche's pharmaceutical innovation.\n\nThe company is best known for pioneering cancer biologics, developing Herceptin (trastuzumab) for HER2-positive breast cancer, Avastin (bevacizumab) for multiple cancers, Rituxan (rituximab) for lymphoma, and Tecentriq (atezolizumab) for PD-L1 immunotherapy. Its discovery engine spans oncology, neuroscience, ophthalmology, and immunology with a robust early-stage pipeline leveraging AI-assisted target identification.\n\nGenentech generates tens of billions in annual revenue through Roche's Pharmaceuticals Division and remains one of the most productive biotech research sites in the world, consistently ranked among top employers in life sciences. The South San Francisco campus employs over 13,000 scientists, clinicians, and engineers, anchoring the Bay Area as a global biotech hub.

Full profile

AI Visibility Head-to-Head

23
Overall Score
85
#1
Category Rank
#1
71
AI Consensus
57
up
Trend
up
26
ChatGPT
77
15
Perplexity
95
21
Gemini
83
21
Claude
87
27
Grok
79

Key Details

Category
Cell Therapy / Liver Disease
Biopharmaceuticals
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Cytotheryx
Cell Therapy / Liver Disease
Only Genentech
Biopharmaceuticals
Genentech is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.